Asset Details
Do you wish to reserve the book?
非小细胞肺癌中EML4-ALK融合及临床治疗进展
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
非小细胞肺癌中EML4-ALK融合及临床治疗进展
Do you wish to request the book?
非小细胞肺癌中EML4-ALK融合及临床治疗进展
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
非小细胞肺癌中EML4-ALK融合及临床治疗进展
2011
Overview
肺癌的死亡率居恶性肿瘤的首位。其中,非小细胞肺癌（non-small cell lung cancer,NSCLC）约占80%,被确诊时多为晚期。传统的化疗能改善近期疗效,对生存期的改善有限,故中位生存时间为12个月左右,预后差[1]。近年来，分子靶向药物治疗正在成为肺癌治疗的热点，如10％，30％的NSCLC患者携带活化的表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变，70％以上的EGFR突变患者对小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKIs）高度敏感，有明显的生存获益。因此，发现和确认肺癌患者的分子亚型，寻找有效的分子靶向治疗靶点是当前需要迫切解决的问题[2]。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.